SCHEMBL716358

SCHEMBL716358

C[C@]12CCCC[C@@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPBAR1 Q8TDU6 3/20 0.68
LMNA P02545 3/20 0.68
CYP3A4 P08684 3/20 0.68
SHBG P04278 2/20 0.68
SERPINA6 P08185 2/20 0.68
HSD17B10 Q99714 2/20 0.68
CYP1A2 P05177 2/20 0.68
CYP2C9 P11712 2/20 0.68
CYP2C19 P33261 2/20 0.68
TSHR P16473 1/20 0.68
KMT2A Q03164 1/20 0.62
PDK1 Q15118 2/20 0.60
PDK2 Q15119 2/20 0.60
PDK3 Q15120 2/20 0.60
PDK4 Q16654 2/20 0.60
CYP19A1 P11511 3/20 0.59
AR P10275 2/20 0.59
NR3C1 P04150 1/20 0.59
PGR P06401 1/20 0.59
NR3C2 P08235 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29362020 1.00 GPBAR1 (0.68) GPBAR1LMNACYP3A4SHBGSERPINA6
SCHEMBL12178029 1.00 GPBAR1 (0.68) GPBAR1LMNACYP3A4SHBGSERPINA6
SCHEMBL12826007 1.00 GPBAR1 (0.68) GPBAR1LMNACYP3A4SHBGSERPINA6
SCHEMBL3366576 1.00 GPBAR1 (0.68) GPBAR1LMNACYP3A4SHBGSERPINA6
SCHEMBL2847894 1.00 GPBAR1 (0.68) GPBAR1LMNACYP3A4SHBGSERPINA6
SCHEMBL24623303 1.00 GPBAR1 (0.68) GPBAR1LMNACYP3A4SHBGSERPINA6
SCHEMBL2593987 1.00 GPBAR1 (0.68) GPBAR1LMNACYP3A4SHBGSERPINA6
SCHEMBL19003336 1.00 GPBAR1 (0.68) GPBAR1LMNACYP3A4SHBGSERPINA6
SCHEMBL716359 1.00 GPBAR1 (0.68) GPBAR1LMNACYP3A4SHBGSERPINA6
SCHEMBL11469831 1.00 GPBAR1 (0.68) GPBAR1LMNACYP3A4SHBGSERPINA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230072025-A1 Stimulation of Human Meibomian Gland Function THE SCHEPENS EYE RESEARCH INSTITUTE 2023-03-09 US claimed
US-9421241-B2 Therapeutic modulation of ocular surface lubrication THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-08-23 US claimed
US-20160015780-A1 Therapeutic Modulation of Ocular Surface Lubrication THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2016-01-21 US claimed
US-9138457-B2 Therapeutic modulation of ocular surface lubrication THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2015-09-22 US claimed
US-20150141328-A1 STIMULATION OF HUMAN MEIBOMIAN GLAND FUNCTION NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2015-05-21 US claimed
US-8980840-B2 Therapeutic modulation of vaginal epithelium boundary lubrication SCHEPENS EYE RESEARCH INSTITUTE (US) 2015-03-17 US claimed
EP-2381957-B1 THERAPEUTIC MODULATION OF VAGINAL EPITHELIUM BOUNDARY LUBRICATION LUBRIS LLC (US) 2015-01-07 EP claimed
US-20120052077-A1 THERAPEUTIC MODULATION OF VAGINAL EPITHELIUM BOUNDARY LUBRICATION LUBRIS LLC 2012-03-01 US claimed
EP-2381957-A2 THERAPEUTIC MODULATION OF VAGINAL EPITHELIUM BOUNDARY LUBRICATION Singularis Inc. (US) 2011-11-02 EP claimed
US-20110070222-A1 Therapeutic Modulation of Ocular Surface Lubrication THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-03-24 US claimed
EP-1175218-A4 OCULAR THERAPY IN KERATOCONJUCTIVITIS SICCA USING TOPICALLY APPLIED ANDROGENS OR TGF-BETA SCHEPENS EYE RES INST (US) 2005-12-21 EP claimed
US-20050014691-A1 Ophthalmic compositions comprising trefoil factor family peptides ALLERGAN, INC. 2005-01-20 US claimed
EP-1175218-A1 OCULAR THERAPY IN KERATOCONJUCTIVITIS SICCA USING TOPICALLY APPLIED ANDROGENS OR TGF-BETA THE SCHEPENS EYE RESEARCH INSTITUTE, INC. (US) 2002-01-30 EP claimed
WO-2000054779-A1 OCULAR THERAPY IN KERATOCONJUCTIVITIS SICCA USING TOPICALLY APPLIED ANDROGENS OR TGF-$g(b) THE SCHEPENS EYE RESEARCH INSTITUTE, INC. (US) 2000-09-21 WO claimed
US-6107289-A Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β THE SCHEPENS EYE RESEARCH INSTITUTE, INC. (US) 2000-08-22 US claimed
EP-0643581-B1 OCULAR ANDROGEN THERAPY IN SJÖGREN'S SYNDROME SCHEPENS EYE RES INST (US) 1999-10-20 EP claimed
US-5620921-A Ocular androgen therapy in sjogren's syndrome THE SCHEPENS EYE RESEARCH INSTITUTE, INC. (US) 1997-04-15 US claimed
EP-0643581-A1 OCULAR ANDROGEN THERAPY IN SJÖGREN'S SYNDROME THE SCHEPENS EYE RESEARCH INSTITUTE, INC. (US) 1995-03-22 EP claimed
EP-0643581-A4 OCULAR ANDROGEN THERAPY IN SJÖGREN'S SYNDROME. SCHEPENS EYE RES INST (US) 1995-01-11 EP claimed
WO-1993020823-A1 OCULAR ANDROGEN THERAPY IN SJÖGREN'S SYNDROME THE SCHEPENS EYE RESEARCH INSTITUTE, INC. (US) 1993-10-28 WO claimed